Table 3

Unadjusted and Adjusted Risk for 3-Year Clinical Outcomes Across Quartiles of Total Stent Length per Patient

n (KM %)Log-Rank p ValueAdjustedp Value for Trend
HR (95% CI)p Value
MACE<0.0001<0.0001
 Quartile 160 (9.2%)Reference
 Quartile 2158 (11.1%)1.13 (0.82–1.56)0.446
 Quartile 3167 (14.4%)1.49 (1.08–2.04)0.014
 Quartile 4260 (19.6%)1.82 (1.34–2.48)<0.001
Key safety endpoint<0.0001<0.001
 Quartile 141 (6.2%)Reference
 Quartile 295 (6.7%)1.15 (0.77–1.70)0.495
 Quartile 3114 (9.8%)1.59 (1.08–2.33)0.018
 Quartile 4173 (12.7%)1.82 (1.25–2.64)0.002
All-cause death0.00620.122
 Quartile 124 (3.8%)Reference
 Quartile 257 (4.2%)1.17 (0.71–1.94)0.538
 Quartile 365 (6.1%)1.65 (1.00–2.71)0.049
 Quartile 478 (6.4%)1.40 (0.85–2.31)0.182
Cardiac death0.01460.038
 Quartile 112 (2.0%)Reference
 Quartile 226 (2.8%)1.24 (0.60–2.57)0.557
 Quartile 337 (4.2%)2.10 (1.05–4.23)0.037
 Quartile 446 (4.6%)1.85 (0.92–3.72)0.086
Myocardial infarction<0.0001<0.001
 Quartile 115 (2.1%)Reference
 Quartile 243 (2.9%)1.47 (0.78–2.78)0.237
 Quartile 360 (4.8%)2.31 (1.24–4.28)0.008
 Quartile 4108 (7.4%)3.12 (1.71–5.70)<0.001
Definite or probable ST0.73930.673
 Quartile 15 (0.7%)Reference
 Quartile 218 (1.2%)1.17 (0.41–3.34)0.773
 Quartile 315 (1.2%)1.21 (0.42–3.50)0.728
 Quartile 415 (1.1%)0.89 (0.30–2.63)0.839
TLR0.00010.011
 Quartile 127 (4.1%)Reference
 Quartile 280 (5.5%)1.00 (0.63–1.59)0.495
 Quartile 368 (6.0%)1.13 (0.70–1.82)0.616
 Quartile 4113 (9.1%)1.51 (0.96–2.39)0.077

The key safety endpoint was defined as a composite of all-cause death, myocardial infarction, or definite or probable ST. MACE was defined as a composite of all-cause death, myocardial infarction, or TLR.

CI = confidence interval; HR = hazard ratio; KM = Kaplan-Meier; MACE = major adverse cardiovascular event; PCI = percutaneous coronary intervention; ST = stent thrombosis; TLR = target lesion revascularization.

  • Adjusted for the following variables using a frailty model: age, hypertension, diabetes, smoking, prior PCI, prior myocardial infarction, PCI indication, and American College of Cardiology/American Heart Association lesion type B2/C.

  • Adjusted for the above variables with trial included as an additional covariate.